NCT05116865View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

May 26, 2022

Study Completion Date

August 2, 2022

Conditions
COVID-19 Respiratory Infection
Interventions
BIOLOGICAL

HH-120 Dose 1

Dose level 1 of HH-120

BIOLOGICAL

HH-120 Dose 2

Dose level 2 of HH-120

BIOLOGICAL

HH-120 Dose 3

Dose level 3 of HH-120

DRUG

Placebo

Placebo to match

Trial Locations (1)

Unknown

Nucleus Network, Brisbane

Sponsors

Lead Sponsor

Huahui Health
All Listed Sponsors
lead

Huahui Health

INDUSTRY

NCT05116865 - A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers | Biotech Hunter | Biotech Hunter